Latest Immutep (Asx:Imm) News

Page 2 of 2
Immutep Limited advances its pivotal Phase III lung cancer trial and reports promising results across multiple oncology and autoimmune programs, supported by a solid cash position to fund operations through 2026.
Ada Torres
Ada Torres
30 July 2025
Immutep reports promising Phase I results for IMP761, a novel LAG-3 agonist antibody demonstrating significant T cell inhibition and a clean safety profile, advancing hopes for new autoimmune disease treatments.
Ada Torres
Ada Torres
23 June 2025
Immutep’s novel immunotherapy combination with radiotherapy and KEYTRUDA® has met its primary endpoint in a Phase II trial for resectable soft tissue sarcoma, showing promising early signs of improved patient outcomes.
Ada Torres
Ada Torres
26 May 2025
Immutep’s novel immunotherapy combination with KEYTRUDA and chemotherapy shows a 60.8% response rate in first-line non-small cell lung cancer, outperforming historical benchmarks especially in patients with low PD-L1 expression.
Ada Torres
Ada Torres
15 May 2025
Immutep’s combination of eftilagimod alfa (efti) and KEYTRUDA® delivers a striking 17.6-month median overall survival in head and neck cancer patients with low PD-L1 expression, a group with limited treatment options.
Ada Torres
Ada Torres
5 May 2025
Immutep Limited has dosed the first patient in its pivotal Phase III lung cancer trial and completed enrolments in multiple studies, supported by a robust cash position expected to fund operations through 2026.
Ada Torres
Ada Torres
29 Apr 2025
Immutep Limited has initiated its pivotal Phase III trial for eftilagimod alfa in first-line non-small cell lung cancer, supported by compelling survival outcomes from ongoing studies and a robust cash position expected to fund operations through 2026.
Ada Torres
Ada Torres
31 Jan 2025